Robert E. Pelzer

Former General Counsel at Novartis Pharmaceuticals Corp.

Robert E. Pelzer

Robert E. Pelzer

Former General Counsel at Novartis Pharmaceuticals Corp.

Overview
Career Highlights

Novartis Pharmaceuticals Corp.
DuPont Pharmaceuticals Co.
Novartis Pharma AG

RelSci Relationships

1777

Number of Boards

9

Birthday

1954

Age

66

Relationships
RelSci Relationships are individuals Robert E. Pelzer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former President & Chief Executive Officer at Arbutus Biopharma Corp.

Relationship likelihood: Strong

Former Chief Financial Officer & Executive Vice President at Novartis Corporation

Relationship likelihood: Strong

Senior Advisor at Baker Bros. Advisors LP

Relationship likelihood: Strong

Executive Partner at Mpm Capital LLC

Relationship likelihood: Strong

Global Chair at GLG Institute

Relationship likelihood: Strong

Former Chief Operating & Medical Officer at CytRx Corp.

Relationship likelihood: Strong

General Partner at Five Corners Capital, Inc.

Relationship likelihood: Strong

Vice President & Treasurer at Novartis Pension Fund

Relationship likelihood: Strong

Former Vice President-Public Affairs at Novartis Corporation

Relationship likelihood: Strong

Executive Director, Venture Capital at Pfizer, Inc.

Relationship likelihood: Strong

Paths to Robert E. Pelzer
Potential Connections via
Relationship Science
You
Robert E. Pelzer
Former General Counsel at Novartis Pharmaceuticals Corp.
Education
Graduate Degree

The University of Alberta (also known as U of A and UAlberta) is a public research university located in Edmonton, Alberta, Canada. It was founded in 1908 by Alexander Cameron Rutherford, the first premier of Alberta, and Henry Marshall Tory, its first president. Its enabling legislation is the Post-secondary Learning Act. The university comprises four campuses in Edmonton, the Augustana Campus in Camrose, and a staff centre in downtown Calgary. The original north campus consists of 150 buildings covering 50 city blocks on the south rim of the North Saskatchewan River valley, directly across from downtown Edmonton. 39,000 students from Canada and 150 other countries participate in 400 programs in 18 faculties. The University of Alberta is a major economic driver in Alberta. The university's impact on the Alberta economy is an estimated $12.3 billion annually, or five per cent of the province's gross domestic product. The university has been recognized by the Academic Ranking of World Universities, the QS World University Rankings and the Times Higher Education World University Rankings as one of the top five universities in Canada and one of the top 100 universities worldwide. According to the 2014 QS World University Rankings, the top Faculty Area at the University of Alberta is Arts and Humanities (ranked 89th in the world), and the top-ranked Subject is English Language and Literature (22nd in the world). The University of Alberta is also a leading institution for the study of Ukraine and is home to the Canadian Institute of Ukrainian Studies. The University of Alberta has graduated more than 275,000 alumni, including Governor General Roland Michener; Prime Minister Joe Clark; Chief Justice of Canada Beverley McLachlin; Alberta premiers Peter Lougheed, Dave Hancock, Jim Prentice and Rachel Notley; Edmonton Mayor Don Iveson and Nobel laureate Richard E. Taylor. The university is a member of the Alberta Rural Development Network, the Association for the Advancement of Sustainability in Higher Education and the Sustainability Tracking, Assessment & Rating System.

Career History
General Counsel
2002 - 2008

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

President & Head-Legal Affairs
2002 - 2008

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Senior Vice President & General Counsel
1998 - 2001

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

Boards & Committees
Member, Advisory Board
Current

Paragon Pharmaceuticals Capital LLC operates as a global development and biopharmaceutical investment firm. It establishes, fosters and manages life science companies. The company was founded in 2009 and is headquartered in Northbrook, IL.

Member, Executive Committee
Prior
Chair, Board of Trustees
Current

The Novartis US Foundation was established in 1997 as part of Novartis' commitment to social investment. Its mission is to support programs within communities and nonprofit organizations on a range of social, health and educational issues. Most of the support provided by the Novartis US Foundation is through matching gifts to education- and healthcare-related 501(c)(3) non-profit organizations receiving donations from US Novartis Group Company associates. Since its inception, this matching gifts program has resulted in the Foundation donating millions of dollars to charitable organizations supported by US Novartis Group Company associates.

Director
Tenure Unconfirmed

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Investments
Details Hidden

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Robert E. Pelzer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Robert E. Pelzer's profile does not indicate a business or promotional relationship of any kind between RelSci and Robert E. Pelzer.